• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    10/18/24 8:45:00 AM ET
    $BOXL
    $CLDI
    $GRRR
    Other Consumer Services
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BOXL alert in real time by email

    ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • Calidi: https://www.redchip.com/assets/access/cldi_access

    • Gorilla Technology: https://www.redchip.com/assets/access/grrr_access

    In an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the multi-billion-dollar oncology field.

    Jay Chandan, Chairman and CEO of Gorilla Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. With over 22 years of operational excellence and a portfolio of 29 granted patents globally, Gorilla has established itself as a leader in delivering transformative solutions that drive large-scale digital transformation. The company's advanced technologies, including edge AI, big data analytics, IoT security, and virtualization infrastructure, empower clients across critical sectors such as government, public safety, manufacturing, and energy management to create smarter, safer and more efficient environments. Gorilla's strong financial foundation, innovative technology, and strategic market expansion provide a solid basis for long-term value creation as it continues to lead in the global digital transformation landscape. Gorilla has buy ratings and a mean price target of $29.50 from three analysts.

    About Calidi Biotherapeutics

    Calidi Biotherapeutics (NYSE:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

    About Gorilla Technology Group Inc.

    Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including, Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.

    Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.

    For more information, please visit our website: https://www.gorilla-technology.com/

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-407-644-4256
    info@redchip.com

    --END--

    SOURCE: RedChip



    View the original press release on accesswire.com

    Get the next $BOXL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • When will the interviews with Calidi Biotherapeutics and Gorilla Technology air?

      The interviews with Calidi Biotherapeutics and Gorilla Technology will air on Bloomberg TV on October 19, 2024, at 7 p.m. Eastern Time.

    • What area of cancer treatment does Calidi Biotherapeutics focus on?

      Calidi Biotherapeutics specializes in oncolytic virotherapy, leveraging engineered viruses to target and destroy cancer cells, while also enhancing immune response to fight tumors.

    • What technologies does Gorilla Technology Group specialize in?

      Gorilla Technology Group is a leader in digital solutions, particularly in edge AI, big data analytics, and IoT security, aimed at transforming operations in government, public safety, and manufacturing.

    • How does Calidi Biotherapeutics' technology differentiate itself in the oncology field?

      Calidi's unique approach involves using stem cell-based platforms that can carry oncolytic viruses, offering a safer and more efficient way to treat cancer.

    • What is the current analyst rating and price target for Gorilla Technology Group?

      Analysts have rated Gorilla Technology with buy ratings and have set a mean price target of $29.50.

    Recent Analyst Ratings for
    $BOXL
    $CLDI
    $GRRR

    CompanyDatePrice TargetRatingAnalyst
    Gorilla Technology Group Inc.
    $GRRR
    12/11/2025$31.00Overweight
    Cantor Fitzgerald
    Boxlight Corporation
    $BOXL
    11/14/2024Buy → Neutral
    Alliance Global Partners
    Calidi Biotherapeutics Inc.
    $CLDI
    11/22/2023$11.00Buy
    H.C. Wainwright
    Calidi Biotherapeutics Inc.
    $CLDI
    10/9/2023$9.00Outperform
    Robert W. Baird
    Gorilla Technology Group Inc.
    $GRRR
    7/26/2023$4.80Overweight
    Cantor Fitzgerald
    Boxlight Corporation
    $BOXL
    12/13/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BOXL
    $CLDI
    $GRRR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gorilla Technology Accelerates Execution Across its Asian AI Infrastructure Platform

    - Recent capital raising supports the execution of signed and developing AI infrastructure programmes - - Yotta deployments progressing ahead of current internal schedules -- Korat 200MW AI data-centre campus advances through power, engineering and customer engagement workstreams -London, United Kingdom--(Newsfile Corp. - July 21, 2026) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global provider of AI-driven infrastructure, security intelligence and data solutions, today announced that the completion of its two recent bond financings, raising aggregate gross proceeds of $232 million, is enabling the Company to accelerate execution across its AI infra

    7/21/26 8:30:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

    Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1 2027  Company demonstrated the versatility of the RedTail platform with new CLD-501 data demonstrating the simultaneous in situ delivery of a TROP-2-targeted tumor-localized T-cell engager (TCE) alongside a T-cell amplifiers. The Company is also advancing its EpCam-targeted In Situ TCE program. In Situ TCEs represent an important advancement of the RedTail platform Strengthened Board of Directors with addition of Corsee Sanders, Ph.D., former executive of Genentech/Roche and CelgeneComp

    7/21/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

    SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the "Reverse Stock Split"). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 31, 2026 under the existing symbol of "CLDI." The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 507. The decision to implement this stock split reflects the Company’s ai

    7/20/26 4:30:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BOXL
    $CLDI
    $GRRR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Gorilla Technology Group with a new price target

    Cantor Fitzgerald initiated coverage of Gorilla Technology Group with a rating of Overweight and set a new price target of $31.00

    12/11/25 9:09:09 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Boxlight downgraded by Alliance Global Partners

    Alliance Global Partners downgraded Boxlight from Buy to Neutral

    11/14/24 7:24:06 AM ET
    $BOXL
    Other Consumer Services
    Real Estate

    H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

    11/22/23 7:15:52 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BOXL
    $CLDI
    $GRRR
    SEC Filings

    View All

    SEC Form 6-K filed by Gorilla Technology Group Inc.

    6-K - Gorilla Technology Group Inc. (0001903145) (Filer)

    7/17/26 4:30:04 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    7/16/26 5:30:30 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Boxlight Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Boxlight Corp (0001624512) (Filer)

    7/2/26 4:34:50 PM ET
    $BOXL
    Other Consumer Services
    Real Estate

    $BOXL
    $CLDI
    $GRRR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Jackson Andrew C. bought $5,000 worth of shares (2,500 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:36 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Poma Eric E bought $50,000 worth of shares (25,000 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:39 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Leftwich Scott bought $250,000 worth of shares (125,000 units at $2.00), increasing direct ownership by 2,212% to 130,650 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:37 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BOXL
    $CLDI
    $GRRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Levy Keith acquired 10,964 units of Ordinary Shares, increasing direct ownership by 27% to 52,075 units (SEC Form 4)

    4 - Gorilla Technology Group Inc. (0001903145) (Issuer)

    7/15/26 6:05:19 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Director Walker Gregg acquired 10,964 units of Ordinary Shares, increasing direct ownership by 25% to 55,572 units (SEC Form 4)

    4 - Gorilla Technology Group Inc. (0001903145) (Issuer)

    7/15/26 6:05:03 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    CEO & Chairman Chandan Jayesh acquired 119,178 units of Ordinary Shares, increasing direct ownership by 11% to 1,214,649 units (SEC Form 4)

    4 - Gorilla Technology Group Inc. (0001903145) (Issuer)

    7/15/26 6:04:33 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    $BOXL
    $CLDI
    $GRRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    12/6/24 9:25:12 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    11/14/24 2:05:25 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    9/17/24 6:53:48 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    $BOXL
    $CLDI
    $GRRR
    Financials

    Live finance-specific insights

    View All

    Gorilla Technology to Host First Quarter 2026 Financial Results Conference Call on May 27 at 4:30 p.m. ET

    London, United Kingdom--(Newsfile Corp. - May 26, 2026) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company") will host a conference call on Wednesday, May 27, 2026, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the quarter ended March 31, 2026. A press release containing the financial results will be issued before the call.Call Date: Wednesday, May 27, 2026 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Toll Free: +1-800-715-9871International: +1-647-932-3411Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty con

    5/26/26 8:00:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Boxlight Reports First Quarter 2026 Financial Results

    Boxlight Corporation (NASDAQ:BOXL) ("Boxlight" or the "Company"), a leading provider of interactive technology solutions, today announced the Company's financial results for the first quarter ended March 31, 2026. Financial and Operational Highlights: Revenue was $22.4 million for the quarter, an increase of 0.1% from the prior year quarter Gross profit margin in Q1'26 decreased to 30.9% from 35.9% from the prior year quarter Net loss was $(6.5) million, compared to net loss of $(3.2) million in the prior year quarter Net loss per basic and diluted common share was $(2.25), compared to $(8.45) net loss per basic and diluted common share in the prior year quarter Adjusted EB

    5/15/26 6:00:00 PM ET
    $BOXL
    Other Consumer Services
    Real Estate

    Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

    Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026Presented new data on RedTail at the AACR conference in San Diego, CA detailing the use of the RedTail platform to create in vivo T-cell engagers that simultaneously express both a T-cell engager and a T-cell activator at high levels exclusively in the tumor microenvironment; presented new data on CLD-501, a TROP-2 in vivo T-cell engagerDemonstrated $1 million reduction in general and administrative expenses from Q1-2025 to Q1-2026Speaker presentation at ASGCT conference in Boston, MA highl

    5/14/26 4:10:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BOXL
    $CLDI
    $GRRR
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.15, which was the closing price of the Company’s common stock on July 6, 2026, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stock Options vesting on the one

    7/8/26 4:05:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

    SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders has an exceptional track record in developing new technologies," said Calidi Chairman of the Board Jim Schoeneck. "We believe her deep expertise in the clinical development of novel therapeutics will be highly valuable as Calidi advances CLD-401 and its RedTail platform into

    6/23/26 8:00:00 AM ET
    $CLDI
    $LEGN
    $RARE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Gorilla Technology Increases Strategic Investment in Astrikos.AI

    - Builds on Q4 investment to further advance Gorilla's integrated AI infrastructure strategy across India, USA, and UAE- Appoints Managing Partner of Gorilla Tech Capital to the board of AstrikosLondon, United Kingdom--(Newsfile Corp. - April 15, 2026) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global solution provider in AI-driven Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today announced that it has increased its strategic investment in Astrikos.AI ("Astrikos"), the Bengaluru, India-based, real-time infrastructure intelligence company, deepening the operational and commercial relationship betw

    4/15/26 8:30:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology